Biosimilar entry onto US market is slow despite implementation of the Biologics Price Competition and Innovation Act (BPCIA) by the Food and Drug Administration (FDA), according to data and analytics company, GlobalData.
Drugs-treatments
The BPCIA was created to abbreviate the pathway for biosimilar drug approval, however, since its implementation in 2010 there are only nine biosimilars available on the US market. As a result of this slow uptake, the agency is taking proactive measures, such as educating patients and physicians through online resources and information campaigns to encourage more competition and lowered prices of biologics.